Date: 2019-07-18Category: Not ApplicableState: Union GovernmentCountry: Europe
Decision of the EEA Joint Committee No 64/2019 of 29 March 2019 amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2019/1228]
**Policy Summary:**
EEA Joint Committee Decision No. 64/2019, dated March 29, 2019, amends Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement. This decision incorporates Regulation (EU) 2018/1718 of the European Parliament and of the Council of November 14, 2018, which pertains to the location of the seat of the European Medicines Agency, into the EEA Agreement. Specifically, the decision adds an indent referring to Regulation (EU) 2018/1718 to point 15zb (Regulation (EC) No 726/2004 of the European Parliament and of the Council) of Chapter XIII of Annex II to the EEA Agreement. The authentic text of Regulation (EU) 2018/1718 in Icelandic and Norwegian will be published in the EEA Supplement to the Official Journal of the European Union. The decision entered into force on March 30, 2019, following the completion of notifications under Article 103(1) of the EEA Agreement. The decision was published in the EEA Section of, and in the EEA Supplement to, the Official Journal of the European Union. The President of the EEA Joint Committee at the time of the decision was Claude Maerten.
Key Entities Referenced
EEA Joint Committee: The decision-making body responsible for amending the EEA Agreement.
EEA Agreement: The Agreement on the European Economic Area, which extends the EU's single market to Iceland, Liechtenstein and Norway.
Regulation EU 2018/1718: A regulation of the European Parliament and of the Council amending Regulation (EC) No 726/2004 regarding the location of the European Medicines Agency.
European Parliament: One of the legislative bodies of the European Union.
Council of the European Union: One of the legislative bodies of the European Union, comprising representatives from each member state's government.
Regulation EC No 726/2004: A regulation concerning the European Medicines Agency.
European Medicines Agency: A decentralised agency of the European Union responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU.
Brussels: The location where the decision was finalized.
L 192/52 EN Official Journal of the European Union 18.7.2019
DECISION OF THE EEA JOINT COMMITTEE No 64/2019
of 29 March 2019
amending Annex II (Technical regulations, standards, testing and certification) to the EEA
Agreement [2019/1228]
THE EEA JOINT COMMITTEE,
Having regard to the Agreement on the European Economic Area (‘the EEA Agreement’), and in particular Article 98
thereof,
Whereas:
(1) Regulation (EU) 2018/1718 of the European Parliament and of the Council of 14 November 2018 amending
Regulation (EC) No 726/2004 as regards the location of the seat of the European Medicines Agency (1) is to be
incorporated into the EEA Agreement.
(2) Annex II to the EEA Agreement should therefore be amended accordingly,
HAS ADOPTED THIS DECISION:
Article 1
The following indent is added in point 15zb (Regulation (EC) No 726/2004 of the European Parliament and of the
Council) of Chapter XIII of Annex II to the EEA Agreement:
‘— 32018 R 1718: Regulation (EU) 2018/1718 of the European Parliament and of the Council of 14 November
2018 (OJ L 291, 16.11.2018, p. 3).’
Article 2
The text of Regulation (EU) 2018/1718 in the Icelandic and Norwegian languages, to be published in the EEA
Supplement to the Official Journal of the European Union, shall be authentic.
Article 3
This Decision shall enter into force on 30 March 2019, provided that all the notifications under Article 103(1) of the
EEA Agreement have been made (*).
Article 4
This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the Official Journal of the European
Union.
Done at Brussels, 29 March 2019.
For the EEA Joint Committee
The President
Claude MAERTEN
(1) OJ L 291, 16.11.2018, p. 3.
(*) No constitutional requirements indicated.